The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
The biology of VEGF and its receptors
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citationA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“, VEGF-A action constitutes a rate-limiting step in normal and pathological blood vessel growt”
BackgroundSelf-citationCombination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
“HIF1alpha binds to promoter elements in the transcriptional region of VEGF-A, an autocrine growth factor that contributes to the process of angiogenesis, and thereby induces its expression [146].”
BackgroundRole of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
“1; for review, see Ferrara et al. 2003).”
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
“angiogenesis associated with tumor growth.(9) It is highly expressed in glioblastoma, and overexpression correlates with high-grade malignancy and poor prognosis.”
BackgroundLenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Molecular regulation of angiogenesis and lymphangiogenesis
Adams, R. H., & Alitalo, K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2183 · Cited by 2,019
“The most important molecule that controls blood-vessel morphogenesis is vascular endothelial growth factor A ( VEGFA ; also known as vascular permeability factor (VPF)), which is part of a large family of potent angiogenic regulators including placental growth factor ( PlGF ), VEGFB, VEGFC and VEGFD (also known as FIGF”
BackgroundTargeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
“Among the three types, VEGFR-1 and VEGFR-2 mainly function in endothelial cells, while VEGFR-3 is present in the lymphatic endothelium.(45) The VEGFR extracellular domain binds to VEGF, leading to the dimerization and phosphorylation of the intracellular tyrosine kinase domain and to the activation of downstream prote…”
BackgroundWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
VEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
“Each family of growth factors (for example, the VEGFs) comprises specific members (for example, VEGF-A) and a series of splice variant isoforms (for example, VEGFA-121, VEGFA-165, VEGFA-189 and VEGFA-206) among which each has a unique role in signaling cascade”
BackgroundComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
“A prominent proangiogenic signaling circuit involves the vascular endothelial growth factor (VEGF) family, and in particular VEGF-A (Ferrara et al., 2003).”
BackgroundInfluentialGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
“VEGFR1 has weak kinase activity with a strong affinity for VEGF and can act as a decoy receptor, competitively reducing VEGF binding to VEGFR2 and therefore regulating VEGF signaling in ECs [12].”
BackgroundAngiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
“The most crucial signaling pathway in physiological and pathological angiogenesis is VEGF-A/VEGFR-2, which stimulates mitosis, chemotaxis, and morphogenesis of ECs, and induces the proliferation, migration, invasion, and angiogenesis in solid tumors.(103) Studies have shown that over-expressed VEGFR-2 has been detecte…”
BackgroundBevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
“In human GBM specimens, the expression of VEGF is associated with a poor prognosis.(10) Conversely, in a xenograft model, antibodies to VEGF have inhibited the growth of GBM.”
BackgroundTyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
“Then, the VEGF family of angiogenic growth factors came to the limelight after the discovery of their pivotal role in vasculogenesis and angiogenesis during embryonic development and under numerous physiologic and pathologic conditions in adults [97].”
BackgroundVascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair
Johnson, K. E., & Wilgus, T. A. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0517 · Cited by 1,100
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
“Vascular endothelial growth factor A (VEGF-A) is a key mediator of physiologic and pathologic angiogenesis.(10) Activities of VEGF-A are mediated by two tyrosine kinase receptors, VEGFR-1 and VEGFR-2.”
BackgroundPhase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
“Time from diagnosis (mo) Median (range) 14 ( 3-66 )”
BackgroundSystemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Self-citationPapadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
“VEGF-A121 is also expressed at high levels in many tissues and in pathological conditions, but it lacks the domains that mediate binding to heparin and neuropilins [17, 18] and is thus freely diffusible.”
BackgroundGavard, J., & Gutkind, J. S. (2006) · Nature Cell Biology · doi:10.1038/ncb1486 · Cited by 1,018
“In adults, deregulated expression of VEGF is involved in a variety of disease states, ranging from inflammation, oedema and thrombotic reactions to cancer and metastasi”
BackgroundHIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S. M., et al. (2008) · Nature · doi:10.1038/nature06613 · Cited by 1,054
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
“in K-ras , p53 , or HER2/ErbB2 ), and persists during progression”
BackgroundTherapeutic strategies for enhancing angiogenesis in wound healing
Veith, A. P., Henderson, K., Spencer, A., Sligar, A. D., & Baker, A. B. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.010 · Cited by 1,021
“The vascular endothelial growth factor (VEGF) family is comprised of five separate growth factors, VEGF-A, -B, -C, -D and placenta growth factor (PlGF) [114].”
BackgroundFDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis
Paik, J.-H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, J. W., Carrasco, D. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.029 · Cited by 1,032
“Relative to Mx-Cre lung ECs, Mx-Cre liver ECs showed enhanced proliferative response to stimulation by VEGF and bFGF, two potent proangiogenic cytokines (Bikfalvi et al., 1997; Ferrara et al., 2003).”
The role of oxygen availability in embryonic development and stem cell function
Simon, M. C., & Keith, B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2354 · Cited by 967
“1b ), including vasculogenesis and angiogenesis”
BackgroundMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Osteogenesis and angiogenesis: The potential for engineering bone
Bone & Joint Research Group, C. F. H. D., Kanczler, J., & Oreffo, R. (2008) · European Cells and Materials · doi:10.22203/ecm.v015a08 · Cited by 987
Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Khansari, N., Shakiba, Y., & Mahmoudi, M. (2009) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/187221309787158371 · Cited by 921
“Some of the well-known activated growth factor receptors that induce ROS include: epidermal growth factor (EGF) receptor, platelet-derived growth factor (PDGF) receptor and vascular endothelial growth factor (VEGF) receptor [30].”
BackgroundKabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Pathophysiological consequences of VEGF-induced vascular permeability
Weis, S. M., & Cheresh, D. A. (2005) · Nature · doi:10.1038/nature03987 · Cited by 909
Biological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Engineered biomaterials for in situ tissue regeneration
Gaharwar, A. K., Singh, I., & Khademhosseini, A. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-0209-x · Cited by 859
Revisiting the hallmarks of cancer.
Fouad, Y. A., & Aanei, C. M. (2017) · Europe PMC (PubMed Central) · Cited by 1,245
The biology of vascular endothelial growth factors
TAMMELA, T., ENHOLM, B., ALITALO, K., & PAAVONEN, K. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.002 · Cited by 838
“VEGFR-3 is present on all endothelia during development but in the adult it becomes restricted to lymphatic ECs and certain fenestrated blood vascular ECs [121,122].”
BackgroundInfluentialInductive angiocrine signals from sinusoidal endothelium are required for liver regeneration
Ding, B.-S., Nolan, D. J., Butler, J. M., James, D., Babazadeh, A. O., Rosenwaks, Z., Mittal, V., Kobayashi, H., Shido, K., Lyden, D., et al. (2010) · Nature · doi:10.1038/nature09493 · Cited by 836
“As the VEGF family plays a critical role in the regeneration of the BM SECs 6 , we hypothesized that VEGF-receptors 20 - 22 , including VEGFR2 or VEGFR3 also modulate LSEC function.”
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
“VEGF-A is a well-characterized regulator of angiogenesis and several anti-VEGF strategies have been implemente”
BackgroundSelf-citationFERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationChemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia
Liu, J.-N., Bu, W., & Shi, J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00525 · Cited by 838
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., Waltari, M., Hellström, M., Schomber, T., Peltonen, R., et al. (2008) · Nature · doi:10.1038/nature07083 · Cited by 813
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Teesalu, T., Sugahara, K. N., Kotamraju, V. R., & Ruoslahti, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908201106 · Cited by 812
“VEGF was originally described as a tumor-secreted vascular permeability factor (15) and later independently cloned as an endothelial cell mitogen (16, 17).”
BackgroundTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
“VEGF and its receptors, VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR), play key roles in the formation and growth of normal blood vessels and in tumor angiogenesis.(14) There is compelling evidence that VEGF is a survival factor for some tumor vessels and that the growth of some tumors is dependent on VEGF-induced angiogene…”
BackgroundTargeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
“Endothelial cells are guided into avascular areas by macromolecules such as VEGFA, a potent pro-angiogenic factor and endothelial cell mitoge”
BackgroundSelf-citationCarano, R. A. D., & Filvaroff, E. H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02866-6 · Cited by 746
URBICH, C., AICHER, A., HEESCHEN, C., DERNBACH, E., HOFMANN, W., ZEIHER, A., & DIMMELER, S. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.07.003 · Cited by 741
“The endothelial cell-specific mitogen and survival factor VEGF also induces increased vascular permeability, proliferation, migration and recruitment of EPC from the bone marrow (reviewed by [34–36]).”
BackgroundDevelopmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Self-citationWiig, H., & Swartz, M. A. (2012) · Physiological Reviews · doi:10.1152/physrev.00037.2011 · Cited by 722
“125, 131, 134, 209) that serve as a reservoir for freely diffusible bioactive molecules available to tissue cells by proteolytic cleavage (131, 201).”
BackgroundLu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703
“VEGF signaling is essential for the specification, morphogenesis, differentiation, and homeostasis of vessels (Gerber et al., 1999, 2002; Helmlinger et al., 2000; Damert et al., 2002; Ferrara et al., 2003).”
BackgroundVEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
Hirakawa, S., Kodama, S., Kunstfeld, R., Kajiya, K., Brown, L. F., & Detmar, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041896 · Cited by 719
Nishijima, K., Ng, Y.-S., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson, S. J., Robinson, G. S., Adamis, A. P., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061237 · Cited by 707
Platelets at the interface of thrombosis, inflammation, and cancer
Franco, A. T., Corken, A., & Ware, J. (2015) · Blood · doi:10.1182/blood-2014-08-531582 · Cited by 691
“Platelets have long been identified as a major source of vascular endothelial growth factor (VEGF),(64,65) platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF), each promoting tumor growth.(66,67) Activation of platelets and release of platelet microparticles leads to the release of a varie…”
BackgroundThe vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
Holmes, D. I. R., & Zachary, I. C. (2005) · Genome biology · doi:10.1186/gb-2005-6-2-209 · Cited by 778
“A cardiomyocyte-specific VEGF-A gene knockout generated using Cre-lox technology results in reduced body weight and thinwalled, dilated, poorly vascularized hearts [1].”
BackgroundInfluentialRomero, R., Nien, J. K., Espinoza, J., Todem, D., Fu, W., Chung, H., Kusanovic, J. P., Gotsch, F., Erez, O., Mazaki-Tovi, S., et al. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050701830480 · Cited by 675
“Most investigators believe that VEGFR-1 might not be a receptor transmitting a mitogenic signal, but rather a ‘decoy’ receptor that prevents the binding of VEGF to VEGFR-2 [56].”
BackgroundInfluentialAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
“Additional mediators of tumor angiogenesis include basic fibroblast growth factor (bFGF/FGF-2), platelet-derived growth factor-B (PDGF-B), stromal cell-derived factor (SDF)-1a, stem cell factor (SCF), interleukin (IL)-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, endothelin-1 (Et-A, Et-B), vashohibin-1/2, thrombospondin (T…”
The roles of vascular endothelial growth factor in bone repair and regeneration
Hu, K., & Olsen, B. R. (2016) · Bone · doi:10.1016/j.bone.2016.06.013 · Cited by 678
“VEGFR2 is the main VEGF signaling receptor and is mostly expressed in endothelial cells to mediate angiogenesis and vasculogenesis, as well as promotion of vessel permeability in response to VEGF [15].”
BackgroundInfluentialSchmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
The Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
Seyfried, T. N., & Shelton, L. M. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-7 · Cited by 644
“In addition to its role in up-regulating glycolysis in response to hypoxia, HIF-1α is also the main transcription factor for vascular endothelial growth factor (VEGF), which stimulates angiogenesis [168,180-182].”
BackgroundThe angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
“VEGF-A is a member of a gene famly that includes placental growth factor (PlGF), VEGF-B, VEGF-C, EGF-D and VEGF-E, all of which bind with varying specificities nd affinities to their bona fide tyrosine kinase receptors, VEGFR, -2 and -3 [4].”
BackgroundBlood–Brain Barrier Pathophysiology in Traumatic Brain Injury
Chodobski, A., Zink, B. J., & Szmydynger-Chodobska, J. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0125-x · Cited by 650
“The two major receptors that VEGFA binds to are receptor tyrosine kinases VEGFR1 (also known as Flt1) and VEGFR2 or KDR/Flk1 [113, 119].”
BackgroundHeart Valve Development: Endothelial Cell Signaling and Differentiation
Armstrong, E. J., & Bischoff, J. (2004) · Circulation Research · doi:10.1161/01.res.0000141146.95728.da · Cited by 647
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
“VEGFR-1, a tyrosine kinase receptor that binds VEGF-A, VEGF-B, and placenta growth factor (7, 8), has been implicated as one of the key regulators of BMDC mobilization and premetastatic priming owing to its expression in a population of hematopoietic progenitor cells and the ability of anti–VEGFR-1 antibodies to reduc…”
BackgroundSelf-citationSchmidt, H. D., & Duman, R. S. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee2aa8 · Cited by 648
“Originally identified as a vascular permeability factor that influences proliferation of endothelial cells (Ferrara et al., 2003),”
BackgroundInfluentialMiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia
Hua, Z., Lv, Q., Ye, W., Wong, C.-K. A., Cai, G., Gu, D., Ji, Y., Zhao, C., Wang, J., Yang, B. B., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000116 · Cited by 655
“When under hypoxia stimulation, VEGF is not the only angiogenic gene up-regulated, as other angiogenic factors have been reported to be up-regulated as well [22,23].”
BackgroundVEGF and Notch in Tip and Stalk Cell Selection
Blanco, R., & Gerhardt, H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006569 · Cited by 620
“2) (Ferrara et al. 2003).”
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Self-citationHu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G. R., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, E. Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 635
A role for VEGF as a negative regulator of pericyte function and vessel maturation
Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., Scheppke, L., Stockmann, C., Johnson, R. S., Angle, N., et al. (2008) · Nature · doi:10.1038/nature07424 · Cited by 629
Rørth, P. (2009) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113231 · Cited by 599
“The original positive trigger for differentiation of a tip cell can be the presence of extracellular VEGF [generally induces vasculature in mammals (Ferrara et al. 2003)] or FGF [for trachea in Drosophila (Ghabrial & Krasnow 2006)], both of which are receptor tyrosine kinase (RTK) ligands.”
BackgroundWang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
“VEGF is a highly bioactive functional glycoprotein that binds to two receptor tyrosine kinases (RTK): Vascular endothelial growth factor receptor (VEGFR) − 1 and VEGFR-2 132 .”
Kelly, B. D., Hackett, S. F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S., Rowan, A., Yan, Z., Campochiaro, P. A., & Semenza, G. L. (2003) · Circulation Research · doi:10.1161/01.res.0000102937.50486.1b · Cited by 611
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
“To date, the VEFG-A/VEGFR2 interaction appears to play a major role in sprouting angiogenesis [7].”
BackgroundFernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600
“of angiogenesis [33–35], on the development and maintenance of hyperdynamic splanchnic circulation and portosystemic collateralization in experimental models of portal hypertension.”
BackgroundKontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
“VEGF receptors (VEGFR1/2) are overexpressed in tumor-associated ECs, with DHA-mediated VEGFR2 suppression linked to the NF-κ B motif [362 – 364].”
Expression and Function of Laminins in the Embryonic and Mature Vasculature
Hallmann, R., Horn, N., Selg, M., Wendler, O., Pausch, F., & Sorokin, L. M. (2005) · Physiological Reviews · doi:10.1152/physrev.00014.2004 · Cited by 574
“6 Signaling via vascular endothelial growth factor (VEGF) (99), originally know as vascular permeability factor (VPF) (155) because of its ability to form edema, is important for several aspects of vessel formation (39, 44, 45, 119).”
BackgroundJunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress
Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouysségur, J., Yaniv, M., & Mechta-Grigoriou, F. (2004) · Cell · doi:10.1016/j.cell.2004.08.025 · Cited by 588
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.